On June 30, TransThera Sciences-B fell 8.18% in regular trading, trading at HK$11.75/share, with turnover of HK$206 million. The stock gave back most of the prior session's gains as the positive sentiment from the company's buyback announcement rapidly dissipated.

The company announced on June 28 a plan to repurchase H shares on the open market for up to RMB 100 million. While this triggered a nearly 20% rally on June 29, the boost proved short-lived. The buyback's limited scale stands in stark contrast to the massive unlock-driven selling pressure: on June 23, approximately 382 million restricted shares — representing over 90% of total share capital — became tradeable following the one-year post-IPO lockup expiry. Major shareholders aggressively sold, causing the stock to plunge over 60% across two trading days, shrinking market capitalization from over HK$11.4 billion to approximately HK$4.1 billion.

The broader biotech sector also traded under pressure, with Akeso down 4.42%, BeiGene down 3.21%, and RemeGen down 6.27%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)